<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999216</url>
  </required_header>
  <id_info>
    <org_study_id>51720</org_study_id>
    <nct_id>NCT03999216</nct_id>
  </id_info>
  <brief_title>Comparing Diuretic Strategies in Hospitalized Heart Failure</brief_title>
  <official_title>Creating a Platform for Point-of-Care Pragmatic Clinical Trials: Comparing Diuretic Strategies in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a pragmatic randomized trial comparing whether using a combination of two
      types of diuretics (loop + thiazide) compared with using a single diuretic (loop only) will
      result in shorter hospital stays for patients hospitalized with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>During hospitalization up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause rehospitalizations, emergency department visits, or death in the 30 days after hospital discharge.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Loop only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loop + Thiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loop Diuretics vs. loop + thiazide diuretics</intervention_name>
    <description>Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.</description>
    <arm_group_label>Loop + Thiazide</arm_group_label>
    <arm_group_label>Loop only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Any adult (age â‰¥18 years) admitted to the Heart Failure Service at Stanford Health Care
        with an indication for treatment with a diuretic.

        Exclusion Criteria:

          1. admission to the intensive care unit or cardiac care units

          2. maintenance dialysis on admission

          3. any mechanical circulatory support on admission

          4. history of heart transplant

          5. allergy / intolerance to loop or thiazide diuretics

          6. admission serum sodium &lt; 125 meq/L (from EPIC)

          7. admission serum potassium &lt; 3.0 meq/L (from EPIC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara Chang, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanford IRB</last_name>
    <phone>1-866-680-2906</phone>
    <email>irbeducation@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tara Chang, MD, MS</last_name>
    </contact>
    <contact_backup>
      <last_name>Shuchi Anand, MD, MS</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Tara I-Hsin Chang</investigator_full_name>
    <investigator_title>Associate Professor of Medicine (Nephrology)</investigator_title>
  </responsible_party>
  <keyword>diuretics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

